Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 701–800 of 1,002
Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential
Antimisiaris, S. G., Mourtas, S., & Παπαδιά, Κ. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.01.056 · Cited by 48
Intracellular Photothermal Delivery for Suspension Cells Using Sharp Nanoscale Tips in Microwells
Man, T., Zhu, X., Chow, Y. T., Dawson, E. R., Wen, X., Patananan, A. N., Liu, T. “., Zhao, C., Wu, C., Hong, J. S., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b06025 · Cited by 48
Nanoparticle Delivery Systems for DNA/RNA and their Potential Applications in Nanomedicine
Shen, H. M., Huang, X., Min, J., Le, S., Wang, Q., Wang, X., Doğan, A. A., Liu, X., Zhang, P., Draz, M. S., et al. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191024170212 · Cited by 48
Marofi, F., Rahman, H. S., Thangavelu, L. P., Dorofeev, A. E., Bayas-Morejón, F., Shirafkan, N., Shomali, N., Chartrand, M. S., Jarahian, M., Vahedi, G., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02251-7 · Cited by 48
“However, these vectors have the risk of inducing mutagenesis, so is not desirable for human [188].”
BackgroundTherapeutic application of RNA interference for hepatitis C virus
Watanabe, T., Umehara, T., & Kohara, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.022 · Cited by 48
Kim, H., Man, H., Saha, B., Kopacz, A. M., Lee, O., Schatz, G. C., Ho, D., & Liu, W. K. (2012) · The Journal of Physical Chemistry Letters · doi:10.1021/jz301756e · Cited by 48
Hung, W. C., Shau, M. D., Kao, H. C., Shih, M. F., & Cherng, J. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.082 · Cited by 48
Elucidation of siRNA complexation efficiency by graphene oxide and reduced graphene oxide
Chau, N. D. Q., Reina, G., Raya, J., Vacchi, I. A., Ménard‐Moyon, C., Nishina, Y., & Bianco, A. (2017) · Carbon · doi:10.1016/j.carbon.2017.07.016 · Cited by 48
Mao, M., Wang, L., Chang, C., Rothenberg, K. E., Huang, J., Wang, Y., Hoffman, B. D., Liton, P. B., & Yuan, F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.009 · Cited by 47
Bioreducible, hydrolytically degradable and targeting polymers for gene delivery
Ullah, I., Muhammad, K., Akpanyung, M., Nejjari, A., Neve, A. L., Guo, J., Feng, Y., & Shi, C. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00275k · Cited by 47
Recent advances in micro/nanoscale intracellular delivery
Sun, M., & Duan, X. (2019) · Nanotechnology and Precision Engineering · doi:10.1016/j.npe.2019.12.003 · Cited by 47
Yu, Z., Hu, P., Xu, Y., Bao, Q., Ni, D., Wei, C., & Shi, J. (2020) · Small · doi:10.1002/smll.201907233 · Cited by 47
Gillet, J., Macadangdang, B. R., Fathke, R. L., Gottesman, M. M., & Kimchi‐Sarfaty, C. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-561-9_1 · Cited by 47
Wang, H., Shayakhmetov, D. M., Leege, T., Harkey, M. A., Li, Q., Papayannopoulou, T., Stamatoyannopolous, G., & Lieber, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.10999-11013.2005 · Cited by 47
Pham, T. T., Chen, H., Nguyen, P. H. D., Jayasinghe, M. K., Le, A. H., & Le, M. T. N. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106665 · Cited by 47
Clinical Application of Adenovirus (AdV): A Comprehensive Review
Salauddin, M., Saha, S., Hossain, M. G., Okuda, K., & Shimada, M. (2024) · Viruses · doi:10.3390/v16071094 · Cited by 46
“Firstly, the vector’s DNA does not integrate into the host cell genome but persists as episomal DNA, particularly prone to loss in dividing cells [45].”
BackgroundBacteriophages as vehicles for gene delivery into mammalian cells: prospects and problems
Bakhshinejad, B., & Sadeghizadeh, M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.927437 · Cited by 46
“Viral vectors can achieve high efficiency in the transduction of mammalian cells being recognized as the most efficient vectors for gene delivery [32].”
BackgroundRole of lipid apheresis in changing times
Schuff-Werner, P., Fenger, S., & Kohlschein, P. (2012) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-012-0049-3 · Cited by 41
“They are easily to be manipulated at the molecular level so that they can be produced at any high titers [46].”
BackgroundMicroRNA as potential modulators in chemoresistant high-grade gliomas
Low, S. Y. Y., Ho, Y. K., Too, H., Yap, C. T., & Ng, W. H. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.07.033 · Cited by 46
“Although the therapeutic effects of adenovirus-mediated co-repression of miR-221 and miR-222 have been reported [87], the use of viruses may have undesirable problems, including provoking an immune response, possible mutagenesis via random insertion of viral sequences into host chromosomes and limited DNA insertion si…”
BackgroundPiersanti, S., Cherubini, G., Martina, Y., Salone, B., Avitabile, D., Grosso, F., Cundari, E., Zenzo, G. D., & Saggio, I. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0543-2 · Cited by 46
“These characteristics avoid recombination phenomena, which have contributed to the doubts raised regarding the clinical safety of eukaryotic virus-derived vectors [1].”
BackgroundHadjizadeh, A., Ghasemkhah, F., & Ghasemzaie, N. (2017) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2017.1292402 · Cited by 46
“However, serious safety risks such as cellular immune response, acute toxicity, and cogenicity have been recognized.(125) In addition, there are still no commercial products approved by the Food and Drug Administration, in spite of the high delivery efficiency of viral vectors.”
BackgroundWang, J., Xie, L., Wang, T., Wu, F., Meng, J., Liu, J., & Xu, H. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.031 · Cited by 46
Chen, W., Zhang, X., Fan, J., Zai, W., Luan, J., Li, Y., Wang, S., Chen, Q., Wang, Y., Liang, Y., et al. (2017) · Theranostics · doi:10.7150/thno.20955 · Cited by 46
“However, application of viral vectors has several limitations including limited DNA packaging capacity, immunogenicity, broad tropism, carcinogenesis and complicated vector production, while hydrodynamic injection is not clinically acceptable [26-29].”
BackgroundPotential Role of MicroRNAs in the Regulation of Antiviral Responses to Influenza Infection
Nguyen, T. H., Liu, X., Su, Z. Z., Hsu, A., Foster, P. S., & Yang, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01541 · Cited by 46
“On the other hand, AAV vectors cause very few side-effects to host because they integrate at limited and defined location in the genome of transfected targets (121, 123).”
BackgroundPro-angiogenic peptides in biomedicine
Rosa, L. D., Stasi, R. D., & D’Andrea, L. D. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.10.010 · Cited by 46
Mable, C. J., Cantón, I., Mykhaylyk, O. O., Gul, B. U., Chambon, P., Themistou, E., & Armes, S. P. (2019) · Chemical Science · doi:10.1039/c8sc05589k · Cited by 46
Layered Double Hydroxide Nanoparticles for Efficient Gene Delivery for Cancer Treatment
Senapati, S., Sarkar, T., Das, P. K., & Maiti, P. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00434 · Cited by 46
Spencer, A. P., Torrado, M., Custódio, B., Silva-Reis, S. C., Santos, S. D., Leiro, V., & Pêgo, A. P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020192 · Cited by 46
“Several types of virus, including retrovirus, adenovirus, adeno-associated virus, and herpes simplex virus, have been explored [12,13].”
Surfactant Protein B Promotes Cytosolic SiRNA Delivery by Adopting a Virus-like Mechanism of Action
Guagliardo, R., Herman, L., Penders, J., Zamborlin, A., Keersmaecker, H. D., de Vyver, T. V., Verstraeten, S. L., Merckx, P., Mingeot‐Leclercq, M., Echaide, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c04489 · Cited by 46
“9 Contrarily, nonviral vectors have gained signi fi cant interest because of their ease of manufacture and fl exible design, as a result of the wide variety of applicable materials and engineering approaches.”
Zhang, C., Chen, S., Li, Q., Wu, J., Qiu, F., Chen, Z., Sun, Y., Luo, J., Bastarrachea, R. A., Grayburn, P. A., et al. (2021) · Small · doi:10.1002/smll.202008177 · Cited by 46
Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia
Guo, J., Cahill, M. R., McKenna, S. L., & O’Driscoll, C. M. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.08.007 · Cited by 46
“In addition, viral particles can be removed from the bloodstreamby pre-existing antibodies and tend to trigger complement and coagulation factor activation, leading to severe immunogenicity problems (Thomas et al., 2003).”
BackgroundBarth, A. S., Kizana, E., Smith, R. R., Terrovitis, J. V., Dong, P., Leppo, M. K., Zhang, Y., Miake, J., Olson, E. N., Schneider, J. W., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.30 · Cited by 46
AEG-1 Promoter–Mediated Imaging of Prostate Cancer
Bhatnagar, A., Wang, Y., Mease, R. C., Gabrielson, M., Sysa, P., Minn, I., Green, G. M., Simmons, B., Gabrielson, K., Sarkar, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0018 · Cited by 46
“By using a biodegradable polymer, in vivo-jetPEI, we tried to avoid certain problems thatmay arise when using viral vectors, such as immune-mediated toxicity, inflammation and liver tropism (41).”
MethodGene Transfer of Cocaine Hydrolase Suppresses Cardiovascular Responses to Cocaine in Rats
Gao, Y., Atanasova, E. A., Sui, N., Pancook, J. D., Watkins, J. D., & Brimijoin, S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.006924 · Cited by 46
“, 2003), both of which can transduce nondividing cells and generate long-term expression in the nervous system (Thomas et al., 2003).”
BackgroundMethodInfluentialFrancis, S. S., Selvin, S., Yang, W., Buffler, P. A., & Wiemels, J. L. (2011) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2011.02.019 · Cited by 46
“While gene therapy constructs using adenoviral vectors caused leukemia in some recipient patients [36], no link to leukemia with natural adenovirus, nor natural vector transmission of this virus, has been reported.”
BackgroundBöldicke, T. W., Weber, H., Mueller, P. P., Barleon, B., & Bernal, M. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.03.007 · Cited by 46
Mechanisms of extracellular vesicle uptake and implications for the design of cancer therapeutics
Jackson, S. R., Flemming, J. P., Karagoz, K., Wermuth, P. J., & Mahoney, M. G. (2024) · Journal of Extracellular Biology · doi:10.1002/jex2.70017 · Cited by 46
Synthetic circRNA therapeutics: innovations, strategies, and future horizons
Cai, J., Qiu, Z., Cho, W. C. S., Liu, Z., Chen, S., Li, H., Chen, K., Li, Y., Zuo, C., & Qiu, M. (2024) · MedComm · doi:10.1002/mco2.720 · Cited by 45
Hellmund, M., Achazi, K., Neumann, F., Thota, B. N. S., Ma, N., & Haag, R. (2015) · Biomaterials Science · doi:10.1039/c5bm00187k · Cited by 45
Nanoscale bio-platforms for living cell interrogation: current status and future perspectives
Chang, L., Hu, J., Chen, F., Chen, Z., Shi, J., Yang, Z., Li, Y., & Lee, L. J. (2015) · Nanoscale · doi:10.1039/c5nr06694h · Cited by 45
Cai, J., Yue, Y., Wang, Y., Jin, Z., Jin, F., & Wu, C. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.031 · Cited by 45
Das, J., Choi, Y., Yasuda, H., Han, J. W., Park, C., Song, H., Bae, H., & Kim, J. (2016) · Scientific Reports · doi:10.1038/srep33784 · Cited by 45
Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis
Villate-Beitia, I., Sesma, J. Z., Puras, G., & Pedraz, J. L. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1298122 · Cited by 45
Octopus-like Flexible Vector for Noninvasive Intraocular Delivery of Short Interfering Nucleic Acids
Jiang, K., Hu, Y., Gao, X., Zhan, C., Zhang, Y., Yao, S., Xie, C., Wei, G., & Lu, W. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02596 · Cited by 45
Gene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration
Vagni, P., Perlini, L. E., Chenais, N. A. L., Marchetti, T., Parrini, M., Contestabile, A., Cancedda, L., & Ghezzi, D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00945 · Cited by 45
Physical approaches for drug delivery
Shinde, P., Kumar, A. S., Kavitha, Dey, K., Mohan, L., Kar, S., Barik, T. K., Sharifi‐Rad, J., Nagai, M., & Santra, T. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817776-1.00007-9 · Cited by 45
Gene Therapy for Huntington’s Disease: The Final Strategy for a Cure?
Byun, S., Lee, M., & Kim, M. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21006 · Cited by 46
Light-activated RNA interference in human embryonic stem cells
Huang, X., Hu, Q., Braun, G. B., Pallaoro, A., Morales, D., Zasadzinski, J. A., Clegg, D., & Reich, N. O. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.06.006 · Cited by 45
Therapeutic ultrasound promotes plasmid DNA uptake by clathrin‐mediated endocytosis
de Paula, D. M. B., Valero, V. B., Paredes‐Gamero, E. J., & Han, S. W. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1586 · Cited by 45
RNA silencing in viral infections: insights from poliovirus
Saleh, M., van Rij, R. P., & Andino, R. (2004) · Virus Research · doi:10.1016/j.virusres.2004.01.010 · Cited by 45
“These methods may therefore encounter similar problems and limitations as gene therapy (Thomas et al., 2003).”
Kim, J., Vaughan, H. J., Zamboni, C. G., Sunshine, J. C., & Green, J. J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.047 · Cited by 44
RNA Therapeutics for Improving CAR T-cell Safety and Efficacy
Schaible, P., Bethge, W. A., Lengerke, C., & Haraszti, R. Á. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2155 · Cited by 44
Efficient non-viral CAR-T cell generation via silicon-nanotube-mediated transfection
Chen, Y., Mach, M., Shokouhi, A., Yoh, H. Z., Bishop, D. C., Murayama, T., Suu, K., Morikawa, Y., Barry, S. C., Micklethwaite, K. P., et al. (2023) · Materials Today · doi:10.1016/j.mattod.2023.02.009 · Cited by 44
Huo, H., Gao, Y., Wang, Y., Zhang, J., Wang, Z., Jiang, T., & Wang, S. (2015) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2015.01.043 · Cited by 44
Advancing Polymeric Delivery Systems Amidst a Nucleic Acid Therapy Renaissance
Burke, P. A., Pun, S. H., & Reineke, T. M. (2013) · ACS Macro Letters · doi:10.1021/mz400418j · Cited by 44
Lee, E. J., Park, H., Jeon, H.-J., Kim, H.-S., & Chang, M. (2013) · Regenerative Medicine · doi:10.2217/rme.13.17 · Cited by 44
Inmunoterapia y terapia génica como nuevos tratamientos contra el cáncer
Rangel‐Sosa, M. M., Aguilar-Córdova, E., & Rojas‐Martínez, A. (2017) · Colombia medica · doi:10.25100/cm.v48i3.2997 · Cited by 44
Raik, S. V., Poshina, D. N., Lyalina, T. A., Polyakov, D. S., Vasilyev, V. B., Kritchenkov, A. S., & Skorik, Y. А. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.11.093 · Cited by 44
Graphene-Based Nanomaterials for Theranostic Applications
Roy, S., & Jaiswal, A. K. (2017) · Reports in Advances of Physical Sciences · doi:10.1142/s2424942417500116 · Cited by 44
Pang, H., Huang, C.-Y., Chou, Y.-W., Lin, C.-J., Zhou, Z.-L., Shiue, Y., Wei, K., & Yang, H. (2019) · Nanoscale · doi:10.1039/c9nr01247h · Cited by 44
Anti-miRNA Oligonucleotide Therapy for Chondrosarcoma
Sun, X., Chen, Y., Yu, H., Machan, J. T., Alladin, A., Ramirez, J., Taliano, R., Hart, J. L., Chen, Q., & Terek, R. M. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1020 · Cited by 44
“Viruses can cause inactivating immune responses and have mutagenic risks (44).”
BackgroundSelf-assembly of poly(allylamine)/siRNA nanoparticles, their intracellular fate and siRNA delivery
Silvio, D. D., Moro, M. M., Salvador, C., Ramírez, M. D. L. Á., Cáceres‐Vélez, P. R., Ortore, M. G., Dupin, D., Andreozzi, P., & Moya, S. E. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2019.09.082 · Cited by 44
Wang, N., Liu, C., Lu, Z., Yang, W., Li, L., Gong, S., He, T., Ou, C., Song, L., Shen, M., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202004940 · Cited by 44
Potta, T., Zhen, Z., Grandhi, T. S. P., Christensen, M. D., Ramos, J., Breneman, C. M., & Rege, K. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.069 · Cited by 44
siRNA nanotherapeutics: a Trojan horse approach against HIV
Mishra, V. K., Kesharwani, P., & Jain, N. K. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.019 · Cited by 44
Vry, J. D., Martínez‐Martínez, P., Losen, M. H., Bode, G. H., Temel, Y., Steckler, T., Steinbusch, H. W. M., Baets, M. H. D., & Prickaerts, J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.62 · Cited by 44
Therapeutics of hearing loss: expectations vs reality
Atar, O., & Avraham, K. B. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03618-4 · Cited by 44
Nanomodification of living organisms by biomimetic mineralization
Chen, W., Wang, G., & Tang, R. (2014) · Nano Research · doi:10.1007/s12274-014-0509-9 · Cited by 44
“But during in vivo tests, they are always recognized as exogenous organisms by human bodies, followed by neutralization and quick clearance [119].”
BackgroundYamamoto, M., & Curiel, D. T. (2005) · Technology in Cancer Research & Treatment · doi:10.1177/153303460500400402 · Cited by 44
Zhang, Y., Huang, C., & Xiong, R. (2024) · Materials Science and Engineering R Reports · doi:10.1016/j.mser.2024.100821 · Cited by 43
Hsu, C. Y. M., Hendzel, M. J., & Uludağ, H. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1526 · Cited by 43
“Disarmed viral particles were initially employed for this purpose but mutagenic and immunogenic concerns prompted the development of safer alternative nonviral gene delivery systems [1].”
BackgroundXue, Y., Liu, M., Lin, P., Huang, S., & Zhuo, R. (2010) · Macromolecular Bioscience · doi:10.1002/mabi.200900300 · Cited by 43
A luminescent tetranuclear ruthenium( ii ) complex as a tracking non-viral gene vector
Yu, B., Chen, Y., Ouyang, C., Huang, H., Ji, L., & Chao, H. (2012) · Chemical Communications · doi:10.1039/c2cc37896e · Cited by 43
El‐Sayed, N. S., Shirazi, A. N., El‐Meligy, M. G., El-Ziaty, A. K., Nagieb, Z. A., Parang, K., & Tiwari, R. K. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.03.020 · Cited by 43
“Moreover, the cationic nature of chitosan and its derivatives has inspired the investigators to use them as promising non-viral gene vectors because of their less cytotoxicity, immunogenicity and mutagenesis response in comparison with the viral vectors and polyarginine or polyethylene imine (PEI) and their ability in…”
BackgroundYuan, C., Chang, C.-T., & Siegel, D. R. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo400695c · Cited by 43
Redox-Sensitive PEG–Polypeptide Nanoporous Particles for Survivin Silencing in Prostate Cancer Cells
Cavalieri, F., Beretta, G. L., Cui, J., Braunger, J. A., Yan, Y., Richardson, J. J., Tinelli, S., Folini, M., Zaffaroni, N., & Caruso, F. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00562 · Cited by 43
Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs
Liu, F., Wang, C., Gao, Y., Li, X., Tian, F., Zhang, Y., Fu, M., Li, P., Wang, Y., & Wang, F. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0338-8 · Cited by 43
Kotcherlakota, R., Vydiam, K., Srinivasan, D. J., Mukherjee, S., Roy, A., Kuncha, M., Rao, T. N., Sistla, R., Gopal, V., & Patra, C. R. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00006 · Cited by 43
Li, X., Zhao, J., Geng, J., Chen, F., Wei, Z., Liu, C., Zhang, X., Li, Q., Zhang, J., Gao, L., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14714 · Cited by 44
Yang, Y., Zhang, W., Liu, H., Jiang, J., Wang, W., & Jia, Z. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s330059 · Cited by 43
Evaluation of a Cationic Poly(β-hydroxyalkanoate) as a Plasmid DNA Delivery System
Sparks, J., & Scholz, C. (2009) · Biomacromolecules · doi:10.1021/bm900372x · Cited by 43
Chen, Z., Penet, M., Krishnamachary, B., Banerjee, S. R., Pomper, M. G., & Bhujwalla, Z. M. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.048 · Cited by 43
“In contrast, viral vectors that are used in gene therapy can induce an immune response and insertional mutagenesis in normal tissues or organs [52].”
Osmon, K. J. L., Woodley, E., Thompson, P., Ong, K., Karumuthil‐Melethil, S., Keimel, J. G., Mark, B. L., Mahuran, D. J., Gray, S. J., & Walia, J. S. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.015 · Cited by 43
“15,16,24,25 A variant of AAV serotype 9, the AAV9.”
Strategies of Conditional Gene Expression in Myocardium
Heine, H. L., Leong, H. S., Rossi, F. M. V., McManus, B. M., & Podor, T. J. (2005) · Methods in molecular medicine · doi:10.1007/978-1-59259-879-3_8 · Cited by 43
Gene Silencing in the Endocrine Pancreas Mediated by Short-Interfering RNA
Bradley, S. P., Rastellini, C., da Costa, M. A., Kowalik, T. F., Bloomenthal, A., Brown, M., Cicalese, L., Basadonna, G. P., & Uknis, M. E. (2005) · Pancreas · doi:10.1097/01.mpa.0000179730.69081.64 · Cited by 43
Gene therapy of liver diseases
Prìeto, J., Qian, C., Hernández-Alcoceba, R., González‐Aseguinolaza, G., Mazzolini, G. D., Sangro, B., & Kramer, M. G. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1073 · Cited by 43
“1 Adenovirus First-generation adenoviral vectors are double-stranded (ds) DNA virions that have a deleted E1 early gene, and have been extensively used for gene therapy of liver diseases in a variety of experimental animals, as well as in Phase I and II clinical trials (reviewed in [9]).”
BackgroundHo, Y. K., Woo, J. Y., Tu, G. X. E., Deng, L., & Too, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-71224-2 · Cited by 42
Therapeutics Based on microRNA: A New Approach for Liver Cancer
Zhang, G., Qizhao, W., & Xu, R. (2010) · Current Genomics · doi:10.2174/138920210791616671 · Cited by 42
“Currently, one of the major barriers to stable gene transfer is the development of transgenespecific immunity [143] because of the direct expression of the transgene product within professional antigen-presenting cells (APCs) of the immune system [144].”
BackgroundNano-enabled drug delivery: A research profile
Zhou, X. H., Porter, A. L., Robinson, D. K. R., Shim, M. S., & Guo, Y. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.03.001 · Cited by 42
Cho, C. (2012) · ISRN Materials Science · doi:10.5402/2012/798247 · Cited by 42
Jeong, C., Yoo, J., Lee, D., & Kim, Y. (2016) · Biomaterials Research · doi:10.1186/s40824-016-0076-0 · Cited by 42
“Among the non-viral gene delivery tools, peptidebased vehicles have been widely used due to their biocompatibility and biodegradability [10–15].”
BackgroundCharacterization of modified mesoporous silica nanoparticles as vectors for siRNA delivery
Slita, A., Egorova, A., Casals, E., Kiselev, A., & Rosenholm, J. M. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.01.006 · Cited by 42
Different-Length Hydrazone Activated Polymers for Plasmid DNA Condensation and Cellular Transfection
Priegue, J. M., Lostalé‐Seijo, I., Crisan, D. N., Granja, J. R., Fernández‐Trillo, F., & Montenegro, J. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00252 · Cited by 42
Batabyal, S., Gajjeraman, S., Pradhan, S., Bhattacharya, S., Wright, W. W., & Mohanty, S. K. (2020) · Gene Therapy · doi:10.1038/s41434-020-00200-2 · Cited by 42
Gupta, P., Kar, S., Kumar, A., Tseng, F., Pradhan, S., Mahapatra, P. S., & Santra, T. S. (2021) · The Analyst · doi:10.1039/d0an02432e · Cited by 42
Virus-inspired nanosystems for drug delivery
Liao, Z., Tu, L., Li, X., Liang, X.-J., & Huo, S. (2021) · Nanoscale · doi:10.1039/d1nr05872j · Cited by 41
Mukherjee, P., Patino, C. A., Pathak, N., Lemaitre, V., & Espinosa, H. D. (2022) · Small · doi:10.1002/smll.202107795 · Cited by 42
Moehler, M. H., Sieben, M., Roth, S., Springsguth, F., Leuchs, B., Zeidler, M., Dinsart, C., Rommelaere, J., & Galle, P. R. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-464 · Cited by 42
“However, many of these vectors are restricted by their pathogenicity and adverse immunological side-effects [9].”
BackgroundCalixarenes and related macrocycles as gene delivery vehicles
Rodik, R. V., Klymchenko, A. S., Mély, Y., & Kаlchеnkо, V. I. (2014) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-014-0412-8 · Cited by 42
“In sharp contrast, calix[4]arene 22 in the 1,3-alternate conformation and calix[6, 8]arenes 24 and 25 formed larger particles (42–146 nm).”
BackgroundInfluentialGene therapies for osteoarthritis
Evans, C. H. (2004) · Current Rheumatology Reports · doi:10.1007/s11926-004-0081-5 · Cited by 42
“(For a comprehensive, recent review see Thomas et al. [ 2 ].) These properties are subject to change as progress is made in modifying and adapting them for new uses; several types of viral vector already have been through several “generations” seeking to improve function.”
Background
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.